Any views expressed within media held on this service are those of the contributors, should not be taken as approved or endorsed by the University, and do not necessarily reflect the views of the University in respect of any particular issue.

UK Cancer Costs Questionnaire

UK Cancer Costs Questionnaire

Information site for the UK Cancer Costs Questionnaire


Information site for the UK Cancer Costs Questionnaire

The UKCC is a modular questionnaire designed to capture the  resources used by people with a current or previous diagnosis of cancer in the context of clinical trials or prospective research and audit

The design prioritises brevity in an attempt to minimise the burden of data collection on participants and research personnel. The tool is designed to be used alongside a clinical trial or trial-standard data collection within an observational study, without duplicating standard data collection on case report forms.

Each question can be used in isolation, but we recommend keeping modules together. The questions can be administered on paper, over the web or over the phone.

Captured activity may currently include NHS primary care, NHS community care, medications and personal social services. Societal costs are also captured including patient out-of-pocket costs, costs incurred by carers and time taken off work.

The UKCC is registered on the DIRUM database.

Version 4 of the UKCC is under development. The questionnaire is likely to fork into curative and palliative contextual versions.

The UKCC development programme is a collaboration between the Health Economics groups at the Universitys of Edinburgh, Leeds and Exeter.


Download the UKCC

Version 3.0 July 2019: UK Cancer Costs Questionnaire v3-0  [Editable version: UK Cancer Costs Questionnaire v3-0 ]

Version 2.7 October 2018:  UK Cancer Costs Questionnaire v2.7

Using the UKCC

Creative Commons Licence
The UKCC is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

The license allows you to use and modify the UKCC, with the understanding that you will make your modified version available to future researchers.

If you are using the UKCC please cite this webpage at

Please let us know at p.s.hall[at] if you are using it. We would love to add your study to our growing list with your modified version below. We seek to learn from new iterations for incorporation into the next version.

Study-specific versions of the UKCC

The tool has been developed in the context of a series of UK clinical trials. Some of the study-specific versions are available to download.

  • Kidney cancer
  • Bowel cancer
    • EMT-2
    • the CITRuS Trial (To examine whether a Complex Intervention protocol decreases Toxicity in patients following Radiotherapy or Surgery for colorectal cancer with electronic data collection, a feasibility trial of data collection. PI Dr Alexandra Stewart, Royal Surrey County Hospital
  • Bladder Cancer

Other studies using the standard version

  • LOGICAN – Oxaliplatin in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

The UKCC has now diversified into post-intensive care follow-up with the ABC Post-ICU Survivourship Trial (CI Prof Tim Walsh, University of Edinburgh).

Example analyses using the UKCC

Marti, J., Hall, P.S., Hamilton, P., Hulme, C.T., Jones, H., Velikova, G., Ashley, L. and Wright, P., 2016. The economic burden of cancer in the UK: a study of survivors treated with curative intent. Psycho‐Oncology25(1), pp.77-83.

Mehanna, H., McConkey, C.C., Rahman, J.K., Wong, W.L., Smith, A.F., Nutting, C., Hartley, A.G., Hall, P., Hulme, C., Patel, D.K. and Zeidler, S.V.V., 2017. PET-NECK: a multicentre randomised Phase III non-inferiority trial comparing a positron emission tomography–computerised tomography-guided watch-and-wait policy with planned neck dissection in the management of locally advanced (N2/N3) nodal metastases in patients with squamous cell head and neck cancer. Health Technology Assessment21(17).

Helena Margaret EarlLouise HillerAnne-Laure VallierShrushma LoiDonna HoweHelen B HigginsKaren McAdamLuke Hughes-DaviesAdrian Nigel HarnettMei-Lin Ah-SeeRichard SimcockDaniel William ReaJanine MansiJean AbrahamCarlos CaldasClaire HulmeDavid MilesAndrew M. WardleyDavid A. CameronJanet Dunn, and PERSEPHONE Trial Investigators PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. 

Journal of Clinical Oncology 2018 36:15_suppl506-506 

Janet DunnLouise HillerClaire BalmerMaggie WilcoxAnne-Laure VallierSophie GassonClaire HulmeDavid MilesAndrew M. WardleyDavid A. CameronHelena Margaret Earl, and the PERSEPHONE Trial Investigators Patient’s perspective of living with and beyond the treatment of trastuzumab: Results from the PERSEPHONE early breast cancer trial.  Journal of Clinical Oncology 2018 36:15_supple22101-e22101 


Hall, C.C., Norris, L., Dixon, L., Cook, J., Maddocks, M., Graham, C., Tuck, S., Haraldsdottir, E., Brown, D., Lloyd, A. and Finucane, A., 2018. A randomised, phase II, unblinded trial of an Exercise and Nutrition-based Rehabilitation programme (ENeRgy) versus standard care in patients with cancer: feasibility trial protocol. Pilot and feasibility studies4(1), p.192. link

Report this page

To report inappropriate content on this page, please use the form below. Upon receiving your report, we will be in touch as per the Take Down Policy of the service.

Please note that personal data collected through this form is used and stored for the purposes of processing this report and communication with you.

If you are unable to report a concern about content via this form please contact the Service Owner.

Please enter an email address you wish to be contacted on. Please describe the unacceptable content in sufficient detail to allow us to locate it, and why you consider it to be unacceptable.
By submitting this report, you accept that it is accurate and that fraudulent or nuisance complaints may result in action by the University.